MX2023009833A - Formulaciones farmaceuticas de cetanafadina y metodos para prepararlas y utlizarlas. - Google Patents
Formulaciones farmaceuticas de cetanafadina y metodos para prepararlas y utlizarlas.Info
- Publication number
- MX2023009833A MX2023009833A MX2023009833A MX2023009833A MX2023009833A MX 2023009833 A MX2023009833 A MX 2023009833A MX 2023009833 A MX2023009833 A MX 2023009833A MX 2023009833 A MX2023009833 A MX 2023009833A MX 2023009833 A MX2023009833 A MX 2023009833A
- Authority
- MX
- Mexico
- Prior art keywords
- centanafadine
- methods
- making
- same
- pharmaceutical formulations
- Prior art date
Links
- HKHCSWPSUSWGLI-CABCVRRESA-N (1r,5s)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane Chemical compound C1=CC=CC2=CC([C@@]34CNC[C@H]4C3)=CC=C21 HKHCSWPSUSWGLI-CABCVRRESA-N 0.000 title abstract 3
- 229950009155 centanafadine Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163152826P | 2021-02-23 | 2021-02-23 | |
| US202163241839P | 2021-09-08 | 2021-09-08 | |
| PCT/JP2022/007314 WO2022181625A1 (en) | 2021-02-23 | 2022-02-22 | Centanafadine pharmaceutical formulations, and methods of making and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009833A true MX2023009833A (es) | 2023-09-04 |
Family
ID=80735736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009833A MX2023009833A (es) | 2021-02-23 | 2022-02-22 | Formulaciones farmaceuticas de cetanafadina y metodos para prepararlas y utlizarlas. |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US11564885B2 (enExample) |
| EP (1) | EP4297734A1 (enExample) |
| JP (2) | JP7787190B2 (enExample) |
| KR (1) | KR20230152046A (enExample) |
| AU (1) | AU2022227367A1 (enExample) |
| BR (1) | BR112023015272A2 (enExample) |
| CA (1) | CA3205786A1 (enExample) |
| IL (1) | IL303767A (enExample) |
| MX (1) | MX2023009833A (enExample) |
| TW (1) | TW202302086A (enExample) |
| WO (1) | WO2022181625A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023015272A2 (pt) * | 2021-02-23 | 2023-11-07 | Otsuka Pharma Co Ltd | Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas |
| KR20250053128A (ko) * | 2022-08-24 | 2025-04-21 | 오츠카 세이야쿠 가부시키가이샤 | 센타나파딘을 포함하는 제약 조성물 |
| US20250375418A1 (en) * | 2022-09-02 | 2025-12-11 | Otsuka Pharmaceutical Co., Ltd. | 1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane for treating major depressive disorder |
| WO2025183181A1 (en) | 2024-02-28 | 2025-09-04 | Otsuka Pharmaceutical Co., Ltd. | Use of centanafadine in treatment of adhd symptoms |
| US12502358B1 (en) | 2024-08-13 | 2025-12-23 | Innovate Therapeutics Llc | Centanafadine multiphasic controlled-release pharmaceutical formulation |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
| DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
| FR2471186A1 (fr) | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
| US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
| US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
| US5225202A (en) | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
| GB9416600D0 (en) * | 1994-08-17 | 1994-10-12 | Smithkline Beecham Plc | Pharmaceutical formulation |
| US6132724A (en) | 1998-04-29 | 2000-10-17 | City Of Hope National Medical Center | Allelic polygene diagnosis of reward deficiency syndrome and treatment |
| US8747895B2 (en) * | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| WO2006133349A2 (en) | 2005-06-08 | 2006-12-14 | Alpharma, Inc. | Orally disintegrable sleep aid formulations |
| EP1915146A4 (en) * | 2005-07-27 | 2010-06-02 | Dov Pharmaceutical Inc | NOVEL 1-ARYL-3-AZABICYCLO [3.1.0] HEXANEES. PREPARATION AND USE FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES |
| ES2529455T3 (es) * | 2006-05-12 | 2015-02-20 | Shire Llc | Sistema de administración de fármacos por dosis controladas |
| US8846100B2 (en) * | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
| US20140206740A1 (en) * | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| CN107335057A (zh) | 2012-07-27 | 2017-11-10 | 韦尔斯利医药有限公司 | 用于缓解尿频的药物制剂及其使用方法 |
| CN106029637A (zh) | 2013-12-09 | 2016-10-12 | 纽罗万斯公司 | 新的组合物 |
| EP3069715A1 (en) * | 2015-03-20 | 2016-09-21 | Salmon Pharma GmbH | Immediate release dosage forms of Atomoxetine |
| US20180008575A1 (en) | 2016-07-11 | 2018-01-11 | Neurovance, Inc. | Methods of treating binge eating disorder |
| BR112023015272A2 (pt) * | 2021-02-23 | 2023-11-07 | Otsuka Pharma Co Ltd | Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas |
-
2022
- 2022-02-22 BR BR112023015272A patent/BR112023015272A2/pt unknown
- 2022-02-22 US US17/677,726 patent/US11564885B2/en active Active
- 2022-02-22 CA CA3205786A patent/CA3205786A1/en active Pending
- 2022-02-22 EP EP22709827.4A patent/EP4297734A1/en active Pending
- 2022-02-22 WO PCT/JP2022/007314 patent/WO2022181625A1/en not_active Ceased
- 2022-02-22 IL IL303767A patent/IL303767A/en unknown
- 2022-02-22 KR KR1020237030686A patent/KR20230152046A/ko active Pending
- 2022-02-22 MX MX2023009833A patent/MX2023009833A/es unknown
- 2022-02-22 AU AU2022227367A patent/AU2022227367A1/en active Pending
- 2022-02-22 TW TW111106378A patent/TW202302086A/zh unknown
- 2022-02-22 JP JP2023547454A patent/JP7787190B2/ja active Active
- 2022-11-30 US US18/072,473 patent/US11759426B2/en active Active
-
2023
- 2023-06-01 US US18/204,728 patent/US11980690B2/en active Active
-
2024
- 2024-01-30 US US18/427,459 patent/US12156941B2/en active Active
- 2024-10-22 US US18/923,418 patent/US12370144B2/en active Active
-
2025
- 2025-06-25 US US19/249,883 patent/US20250319030A1/en active Pending
- 2025-08-13 JP JP2025134582A patent/JP2025183214A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022227367A1 (en) | 2023-08-03 |
| US20250041225A1 (en) | 2025-02-06 |
| US11564885B2 (en) | 2023-01-31 |
| US20230338293A1 (en) | 2023-10-26 |
| JP7787190B2 (ja) | 2025-12-16 |
| TW202302086A (zh) | 2023-01-16 |
| US20240165030A1 (en) | 2024-05-23 |
| JP2024506595A (ja) | 2024-02-14 |
| EP4297734A1 (en) | 2024-01-03 |
| US11980690B2 (en) | 2024-05-14 |
| US12156941B2 (en) | 2024-12-03 |
| AU2022227367A9 (en) | 2024-10-17 |
| US11759426B2 (en) | 2023-09-19 |
| IL303767A (en) | 2023-08-01 |
| JP2025183214A (ja) | 2025-12-16 |
| US20250319030A1 (en) | 2025-10-16 |
| US20220265557A1 (en) | 2022-08-25 |
| BR112023015272A2 (pt) | 2023-11-07 |
| CA3205786A1 (en) | 2022-09-01 |
| WO2022181625A1 (en) | 2022-09-01 |
| US12370144B2 (en) | 2025-07-29 |
| US20230104529A1 (en) | 2023-04-06 |
| KR20230152046A (ko) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023009833A (es) | Formulaciones farmaceuticas de cetanafadina y metodos para prepararlas y utlizarlas. | |
| AU2018231044A8 (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
| PH12020550341A1 (en) | Niraparib formulations | |
| CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
| NO20050018L (no) | Lasofoxifentabletter og belegg | |
| MX2020013785A (es) | Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo. | |
| MX2025010193A (es) | Formas cristalinas de estado solido de un modulador selectivo de canales de potasio | |
| NO20060991L (no) | Feksofenadinsammensetning og fremgangsmate til fremstilling | |
| MY206893A (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
| MX2025000572A (es) | Formulaciones de capsula de cubierta blanda y metodos de preparacion y uso de las mismas | |
| WO2019203771A3 (en) | Solid oral pharmaceutical compositions comprising sitagliptin | |
| MX2023005913A (es) | Derivados de bencenosulfonamida y usos de los mismos. | |
| MX2025012658A (es) | Composicion farmaceutica que contiene oseltamivir | |
| MX2025010834A (es) | Formulaciones de un profarmaco antiviral | |
| MX2025008658A (es) | Composiciones farmacéuticas de propelente ecológico | |
| IL283405A (en) | Formulations, methods, kits and dosage forms to improve the stability of an active medicinal component | |
| PE20220381A1 (es) | Formulacion de tableta vaginal | |
| WO2020190900A8 (en) | Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof | |
| CO2019011299A2 (es) | Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4 | |
| MX2024004013A (es) | Composiciones liquidas orales de enzalutamida. | |
| MX2023013144A (es) | Tableta erosionable. | |
| HK40104596A (en) | Centanafadine pharmaceutical formulations, and methods of making and using same | |
| MX2022015438A (es) | Formulaciones de tableta dispersable que comprenden dolutegravir. | |
| MX2021004553A (es) | Composiciones farmaceuticas y metodos para fabricar formulaciones de dosificacion solidas bajo demanda. | |
| WO2022146355A3 (en) | Pharmaceutical capsule compositions of alogliptine |